Kornimate/medical-research-clean huggingface dataset:
an exploration of apatinib combined with s-1 in patients with advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this study is to explore the potential efficacy and safety of low-dose apatinib combined with s-1 in patients with advanced lung cancer. patients with advanced nsclc will be treated with oral apatinib and s-1 after treatment failure of standard regimen.

apatinib is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor receptor-2 (vegfr-2). the anti-angiogenesis effect of apatinib has been proved in preclinical tests. phase ii study has showed an improvement of progression free survival in pretreated patients. s-1, an oral fluoropyrimidine has considerable effectiveness with mild side effect in patients failed to standard treatments. the purpose of this study is to evaluate the potential efficacy and safety of low-dose apatinib combined with s-1 in heavily pretreated patients with advanced lung cancer. and to explore the biomarkers of antiangiogenesis therapy and the possible mechanisms of treatment resistance on the basis of next generation sequencing.

Eligibility criteria:
inclusion criteria: * pathologically confirmed non-small cell lung cancer * patients with extracranial measurable lesions * patients with nsclc failed for standard treatments * eastern cooperative oncology group performance status score: 0\~2 and life expectancy of more than 3 months * major organs functioning properly * compliance is good and agreed to cooperate with the survival of follow-up * informed consent exclusion criteria: * contraindications for investigational agents * patients with clinical symptoms of brain metastases or meningeal metastasis * tumor invade big vessels or close to big vessels * uncontrolled hypertension * abnormal coagulation (inr\>1.5 or prothrombin time\>uln+4, or activated partial thromboplastin time\>1.5 uln), bleeding tendency or receiving coagulation therapy * hemoptysis, more than 2.5ml daily * thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis. * myocardial ischemia or infarction more than stage ii, cardiac insufficiency. * received big surgery, had bone fracture or ulcer in 4 weeks. * urine protein≥++, or urine protein in 24 hours≥1.0g

Keywords: non-small cell lung cancer apatinib s1
retrospective survey evaluating the effectiveness and safety of dual inhibition lipid-lowering in the treatment of dyslipidemia (study p05171)(completed)

Conditions: Dyslipidemia

Summary: this retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their normal standard of care. this study assesses the percentage of patients who achieve ldl-c target goals and also evaluates the patient compliance to treatment.

retrospective medical chart review

Eligibility criteria:
inclusion criteria: * patient was \> 20 years and \< 75 years of age on the index date\* * patient diagnosed with dyslipidemia who did not respond adequately based on ncep atp iii target to previous lipid lowering treatment, and have received dual inhibition therapy, such as ezetimibe plus statins, ezetimibe plus fenofibrate or ezetimibe alone, for at least 3 months * patient has at least one total cholesterol and ldl-c measurements at baseline and 3 months after initiating the dual inhibition therapy. * patient has the following records documented in the chart during the data collection period: * medical history and co morbidities (if available) * total cholesterol and ldl-c. test results before and after initiating the dual inhibition therapy * prescription information of lipid-lowering dual inhibition regimens note: \* index date: the date of initiating dual inhibition therapy exclusion criteria: * patients who do not meet all the inclusion criteria will be excluded from this survey. * patients who were enrolled in other clinical trial observing specific study procedures which deviates from normal practice will not be included in this study.
sustained onabotulinumtoxina therapeutic benefits in patients with chronic migraine

Conditions: Migraine Disorders

Summary: to assess whether there is a sustained benefit and good safety with repeated onabotulinumtoxina sessions in chronic migraine over more than three years of treatment. we prospectively enrolled 65 chronic migraine patients, who were classified as responders after three sessions of onabotulinumtoxin a and were eligible to further continue treatment.

evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxina (botox®) in chronic migraine (cm) patients is maintained over long term treatment is still limited. this study aims at assessing whether there is a sustained benefit and good safety with repeated onabotulinumtoxin a sessions in cm over more than three years of treatment. this study prospectively enrolled 65 cm patients, who were classified as responders after three sessions of onabotulinumtoxina and were eligible to further continue treatment. data documenting longitudinal changes from the trimester after the third onabotulinumtoxina administration (t1) to the trimester after completing two years of treatment (t2) and eventually to the trimester after completing three years of treatment (t3) in (i) mean number of monthly headache days (ii) migraine severity as expressed by the mean number of days with peak headache intensity of \>4/10, and (iii) mean number of days with use of any acute headache medication, were prospectively collected from patients' headache diaries.

Eligibility criteria:
inclusion criteria: * patients diagnosed with chronic migraine according to ihc-iii with or without medication overuse. * responders defined as patients that after 3 sessions of treatment with onabutulinum toxin a, having experienced a ≥50% reduction in their average monthly migraine days exclusion criteria: -
nutritional aspects of rett syndrome

Conditions: Rett Syndrome

Summary: objectives: i. determine dietary macronutrient intake in children with rett syndrome and in healthy controls. ii. measure sleeping and awake metabolic rates in various positions, i.e., reclining, sitting, and standing, by whole-room indirect calorimetry and isotope dilution. iii. quantify activity patterns by time-motion studies using 24-hour activity records and 12-hour videotaping. iv. correlate 24-hour activity patterns with 24-hour heart rate telemetry and short-term oxygen consumption. v. estimate 24-hour fecal and urinary energy losses. vi. determine body composition by clinical anthropometry, whole-body potassium counting, and total-body electrical conductance. vii. calculate apparent energy needs based on measurement of energy intake and expenditure.

protocol outline: all participants undergo extensive nutritional and metabolic assessment with body composition evaluation. studies include macronutrient intake, body fat, lean muscle mass, metabolic rate, and time-action studies; and 24-hour cardiac telemetry. rett syndrome girls also receive a hemogram and hand x-ray.

Eligibility criteria:
protocol entry criteria: patients aged 5 to 18 with rett syndrome able to sleep and awaken alone

Keywords: rett syndrome neurologic and psychiatric disorders rare disease
detecting early heart failure in greater manchester

Conditions: Heart Failure

Summary: heart failure represents a growing public health problem within the uk and particularly within the north west of england. a major challenge is that heart failure is currently diagnosed too late. the researchers have previously developed a risk calculator that accurately identifies individuals at risk of heart failure admission or death before they have developed heart failure. most risk calculators are never implemented into clinical practice. the researchers will l perform a pilot study to evaluate the risk calculator within primary care in greater manchester.

the researchers have previously developed and externally validated a novel multimodal risk calculator that accurately identifies individuals at-risk of heart failure admission or death before they have developed heart failure. this risk calculator includes key co-morbidities, circulating biomarkers and cardiac magnetic resonance imaging (cmr) measurements of cardiac structure and function. it identifies those individuals at highest risk of developing heart failure and therefore those who may most benefit from targeted cardiometabolic therapeutics in the future. the researchers will l perform a pilot study to evaluate the risk calculator within primary care in greater manchester. a qualitative and quantitative assessment of risk calculator uptake will be performed within local gp practices and primary care populations. the research team will determine how effectively they can recruit participants from socioeconomically deprived and ethnically diverse backgrounds. a preliminary analysis will be performed to determine risk calculator accuracy within a prospective primary care cohort, and dynamically refine the model aiming to improve performance. the study will also involve conducting an initial cost effectiveness analysis to determine the real-world economic impact of model implementation.

Eligibility criteria:
inclusion criteria: * written informed consent * aged 50 and over * two or more of the following conditions: type 2 diabetes, chronic obstructive pulmonary disease, ischaemic heart disease, atrial fibrillation, hypertension, chronic kidney disease stage 3, body mass index ≥ 30 kg/m2 exclusion criteria: * established diagnosis of one or more of the following: heart failure, cardiomyopathy, moderate or severe valvular heart disease, congenital heart disease, heart transplant, idiopathic, heritable or drug-induced pulmonary arterial hypertension, any medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study. * contraindication to cardiovascular magnetic resonance (cmr) scanning, including pacemaker, defibrillator, intraocular metal, intracranial aneurysm clips, severe claustrophobia, estimated glomerular filtration rate \< 30 ml/min/1.73m2, previous severe allergic reaction or anaphylaxis to gadolinium-based contrast agent, pregnancy or breastfeeding.
helicobacter pylori in patients with chronic tonsillits prepared for tonsillectomy

Conditions: Helicobacter Pylori Infection in Patients With Chronic Tonsillits

Summary: tonsillar disorders are frequent in both pediatric and adult otolaryngological practice, . numerous disorders that damage tonsillar tissue necessitate tonsillectomy. tonsillectomy is typically required for recurrent tonsillitis. (mani et al., 2019). according to studies, the mucosa-associated lymphoid tissue (malt) of the stomach and tonsillar tissue in the waldeyer's ring are both lymphoid tissues (ma et al., 2018). one of the most prevalent and frequent conditions in otorhinolaryngology is chronic tonsillitis, which is mostly brought on by bacterial infection. chronic tonsillitis attacks can affect not only the tonsillar tissue but also can contribute to the emergence and progression of systemic disorders (alrayah.,2023). a gram-negative, urease-producing bacterium called helicobacter pylori colonizes the mucosa of the digestive tract. it has been linked to gastric malignancies, notably mucosa-associated lymphoid tissue (malt) lymphoma, as well as gastric ulcers and duodenal ulcers (kusters et al., 2006).


Eligibility criteria:
inclusion criteria: 1. age: 5 to 50 years. 2. of both sex. 3. diagnosed with chronic tonsillitis undergoing elective tonsillectomy exclusion criteria: 1. patients on proton pump inhibitor or antibiotics 2 weeks before surgery . 2. immune-compromised patients. 3. patients with obstructive sleep apnea candidates for adenotonsillectomy
vitrectomy with planned foveal detachment for refractory dme with or without vitreo-macular interface abnormality

Conditions: Chronic Edema of the Macula

Summary: to evaluate the therapeutic efficacy of sub retinal bss injections in conjunction with conventional vitrectomy for refractory diabetic macular edema (dme)- resistant to more than one anti-vegf agent, intravitreal corticosteroids and to previous vitrectomy. some of enrolled cases had normal vitreo-macular interface (vmi) relationship, while other cases had incomplete vitreoretinal separation with vitreomacular attachment (vma).


Eligibility criteria:
inclusion criteria: * cases with refractory dme with a central macular thickness (cmt) of more than 300 µm despite undergoing anti-vegf therapy (5-6 monthly injections of ranibizumab (ivr) or bevacizumab (ivb) with shifting to aflibercept (iva) for additional 3 injections). exclusion criteria: * the major exclusion criteria were: (1) presence of apparent retinal pigment epithelium (rpe) atrophy at or near the macula; (2) presence of proliferative diabetic fibrovascular membranes threating or at the macula; (3) presence of diabetic optic atrophy; and (4) presence of neovascular glaucoma.
assesment of tonsil volume with ultrasonography in both children and adults

Conditions: OSAS; Recurrent Tonsillitis

Summary: the tonsil volume is an important factor in the decision of the tonsillectomy operation. for this reason, it is important to evaluate the tonsil size before the surgery. ultrasonography was used in a limited number of studies about tonsil tissue assessment and also those studies include only the pediatric population. in this study, we investigate the success of ultrasonography in adults additionally pediatric population as a contribution to literature.

tonsillectomy is a common procedure performed on both adults and children. recurrent tonsillitis, snoring and obstructive sleep apnea is among the most important indications for this surgery. tonsil volume, in addition to recurrent tonsillitis frequency, are both considered in deciding tonsillectomy operation. moreover, recent studies showed a correlation between tonsil hypertrophy and tonsillitis frequency. for this reason, a reliable assessment of tonsil volume is crucial both during clinical follow-up and surgery decision. today, a number of clinical staging systems are used to assess tonsil volume; with 'friedman scale' and 'brodsky scale' being the most commonly used systems. those staging systems employ physical examination and are graded on palatine tonsils' midline extension. in other words, clinical staging uses just the transverse length of tonsils and vertical length and depth are dismissed. in addition, other factors such as patient non-compliance, size of the tongue and tongue base, hyperactive gag reflex and trismus make a clinical assessment difficult. for those reasons, a correct clinical assessment of tonsil volume is not always conceivable. ultrasonography (usg) was used in a limited number of studies about tonsil tissue assessment despite high patient compliance, low cost and its non-radioactive nature. also, those studies include only the pediatric population.in this study, we would like to assess the success of usg in objective measurement of tonsil volume in both pediatric and adult populations and comparison of those results with clinical findings

Eligibility criteria:
inclusion criteria: * tonsillectomy patients with recurrent tonsillitis * tonsillectomy patients with obstructive sleep apnea syndrome. exclusion criteria: -tonsillectomy patients with suspected malignancy

Keywords: size tonsil tonsillectomy ultrasonography
sugammadex given for the reversal of rocuronium induced neuromuscular blockade under sevoflurane anesthesia in infants

Conditions: Brain Cancer

Summary: the objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients


Eligibility criteria:
inclusion criteria: * patients between the ages of 1-12 month, * asa physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study exclusion criteria: * younger than 1month or older than 12 months. * hepatic or renal failure * a history of allergy to study medication

Keywords: sugammadex rocuronium infant patients
effect of citalopram on chest pain in patients with functional chest pain

Conditions: Functional Chest Pain

Summary: non-cardiac chest pain (nccp) in the absence of musculoskeletal abnormalities, major esophageal motor disorders, gastroesophageal reflux or eosinophilic esophagitis is called functional chest pain (fcp). most likely multiple factors play a role, such as esophageal hypersensitivity and enhanced perception. citalopram and other antidepressants are proven to be effective in the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. with this trial the investigators want to assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.

chest pain can be divided in cardiac or non-cardiac chest pain (nccp). to establish the diagnosis nccp, acute coronary disease has to be ruled out first. nccp can be caused by functional chest pain (fcp). nccp in the absence of musculoskeletal abnormalities, major esophageal motor disorders, gastroesophageal reflux or eosinophilic esophagitis is called fcp. the pathophysiology is not fully understood. most likely multiple factors play a role, such as esophageal hypersensitivity and enhanced perception. citalopram and other antidepressants are proven to be effective in the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. however, available data regarding low dose antidepressants in functional chest pain is inconclusive. moreover, all current evidence concerning the effect of low dose antidepressants in patients with functional chest pain is extracted from trials that pooled patients with different functional esophageal disorders. with this trial the investigators want to assess the effect of citalopram on symptoms of chest pain in patients with functional chest pain.

Eligibility criteria:
inclusion criteria: * written informed consent * minimum age: 18 years * functional chest pain according to rome iv criteria * ruled out cardiac origin of chest pain * ecg with corrected qt interval (qtc) within the normal range (\<450ms male, \<460ms female) * symptoms of chest pain for at least 6 months * frequency of symptoms at least once a week * gastroduodenoscopy, high-resolution manometry and 24-hour ph-impedance monitoring need to have been performed recently. exclusion criteria: * currently using antidepressants * contraindication for the use of ssri * already tried antidepressants off-label to treat chest pain * known allergy to citalopram * severe and clinically unstable concomitant disease * pregnant, lactating or fertile women (without contraception)
role of gene variation in effectiveness of gleevec treatment

Conditions: Cancer; Breast Cancer

Summary: this study will examine dna from cancer patients previously treated with gleevec to look for a variation (mutation) of the abcg2 gene that may render the drug less effective in certain patients. gleevec is used to treat chronic myeloid leukemia and gastrointestinal tumors. although most patients respond to treatment, many with advanced disease develop resistance to the drug. it is thought that in some patients this resistance results from the action of a protein that causes gleevec to be pumped out of the cells, reducing its usefulness. patients enrolled in clinical trials of gleevec at the national cancer institute and at other participating institutions are eligible for this study. dna from patients' blood samples are analyzed for the abcg2 gene and correlated with clinical data, such as the patient's age, race, disease state, weight, height, and body surface area. it will also look at the drug dose, how often the drug is given, the duration of treatment, side effects and other medications taken.

abcg2, also known as breast cancer resistance protein (bcrp), is an atp-binding cassette (abc) transporter that has been shown to confer resistance to several drugs, including mitoxantrone and topotecan. gleevec (imatinib mesylate) has recently been identified as a substrate for abcg2. the expression of abcg2 in the human jejunum has been shown to be higher than expression mdr1, which encodes for p-glycoprotein. therefore, it is plausible that the oral bioavailability of gleevec could be dependent on the extent of transport. a single nucleotide polymorphism (c421a) has been identified in abcg2 and has been shown in vitro to result in functional inactivation of this transporter protein. in this study, the relationship between the genotypes of abcg2 and the pharmacokinetics or side effects will be retrospectively explored in patients with cancer who had been previously enrolled on clinical trials of gleevec.

Eligibility criteria:
* inclusion criteria: in this retrospective study, all cancer patients enrolled on irb approved clinical trials of gleevec from both the national cancer and outside institutions will be eligible, provided that they have consented in the original consent form. exclusion criteria: not applicable.

Keywords: pharmacogenetics transporter proteins drug exposure imatinib retrospective cancer
tdcs for multiple system atrophy with cerebellar feature

Conditions: Multiple System Atrophy, Cerebellar Variant (Disorder)

Summary: the aim of study is to investigate most effective site for control the motor coordination using transcranial direct current stimulation in multiple system atrophy with cerebellar feature

participants receive transcranial direct current stimulation (tdcs) over m1, cerebellar cortex or sham stimulation for 30 minutes. the type of stimulation depends on random assignment. the participants have a 1 week of wash out period between each stimulation. the assessment will be done by international cooperative ataxia rating scale (icars), gaitrite (cir systems inc., clifton, new jersey, usa) and pedoscan (diers pedo, germany) at baseline and immediately after each treatment.

Eligibility criteria:
inclusion criteria: * 1. patients who meet the clinical criteria for probable multiple system atrophy with cerebellar features (mds second consensus statement on the diagnosis of multiple system atrophy) * 2. patients aged between 40 and 70 * 3. patients who do not have rigidity and bradykinesia * 4. patients who have given voluntary consent after understanding the content of the clinical trial exclusion criteria: * 1. patients with a serious cognitive disorder, behavioral disorder, or mental illness * 2. patients have history of seizure, stroke, encephalitis, other degenerative neurological disease * 3. patients with a serious medical disease * patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, moderate or more severe liver disease * patients with un-controlled high blood pressure or diabetes * 4. patients who have taken another investigational products within 4 weeks prior to being enrolled in this clinical trial, or patients who are pregnant or breastfeeding

Keywords: multiple system atrophy cerebellar ataxia transcranial direct current stimulation